Table 1 The demographics and clinical characteristics of patients in the IgAN group and in the disease control group
IgAN | DC | P value | |
|---|---|---|---|
Sex (male/female) | 106/71 | 91/66 | 0.704 |
Age (years) | 35.62 ± 11.87 | 41.81 ± 13.70 | < 0.001 |
MAP (mmHg) | 100.02 ± 12.60 | 97.40 ± 12.33 | 0.055 |
TP (g/L) | 64.24 ± 8.99 | 51.29 ± 10.74 | < 0.001 |
Alb (g/L) | 38.06 ± 6.37 | 27.80 ± 8.2 | < 0.001 |
Scr (μmol/L) | 100.10 (77.08, 148.95) | 72.50 (58.85, 93.710) | < 0.001 |
UA (μmol/L) | 398.58 ± 103.35 | 360.61 ± 105.06 | 0.001 |
BUN (mmol/L) | 6.91 ± 3.87 | 6.17 ± 4.44 | 0.103 |
Proteinuria (g/24 h) | 1.41 (0.72, 2.95) | 3.18 (1.65, 5.21) | < 0.001 |
< 1 n (%) | 65 (36.7) | 24 (15.3) | |
1~3.5 n (%) | 80 (45.2) | 58 (36.9) | |
≥ 3.5 n (%) | 32 (18.1) | 75 (47.8) | |
CKD stage | 177 | 157 | < 0.001 |
CKD1 stage n (%) | 56 (31.6) | 110 (70.1) | |
CKD2 stage n (%) | 51 (28.8) | 27 (17.2) | |
CKD3 stage n (%) | 54 (30.5) | 15 (9.6) | |
CKD4 stage n (%) | 16 (9.1) | 5 (3.2) |